Dabur is exiting the pharma business. The Burman family, promoters of FMCG major Dabur, has sold the oncology drug manufacturing company - Dabur Pharma - to European healthcare major Fresenius SE for about Rs 880 crore.
The Burmans, along with some key stakeholders, have agreed to sell their 73.27 per cent stake at a price of Rs 76.50 per share, a 10 per cent premium over the current market price. The deal values Dabur Pharma at Rs 1198.75 crore.
When contacted, Anand Burman, chairman of Dabur declined to comment on the deal. The acquisition will be routed through the European company
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app